Arcutis posted Q4 2025 total revenues of USD 129.5 million, including net product revenue of USD 127.5 million (+84% YoY; +29% QoQ) from ZORYVE and other revenue of USD 2.0 million. Q4 cost of sales was USD 11.7 million, R&D expenses were USD 20.5 million, and SG&A expenses were USD 79.0 million. Net income was USD 17.4 million (USD 0.14 per basic share; USD 0.13 per diluted share), and cash, cash equivalents, restricted cash and marketable securities totaled USD 221.3 million at Dec. 31, 2025; operating cash flow was USD 26.2 million in Q4. For FY 2025, Arcutis reported total revenues of USD 376.1 million, including net product revenue of USD 372.1 million (2.2x YoY) and other revenue of USD 4.0 million. FY 2025 cost of sales was USD 36.7 million, R&D expenses were USD 77.1 million, SG&A expenses were USD 274.6 million, and net loss was USD 16.1 million (USD 0.13 per basic and diluted share). The company raised FY 2026 net product revenue guidance to USD 480 million–USD 495 million. Business updates included Medicare access beginning in January 2026, the October 2025 FDA approval and launch of ZORYVE cream 0.05% for atopic dermatitis in children ages 2 to 5, and plans to expand its dermatology sales force while assuming responsibility for pediatric and primary care promotion following termination of the Kowa promotion agreement in January 2026. Arcutis said an sNDA for ZORYVE cream 0.3% to treat plaque psoriasis down to age 2 has a PDUFA target action date of June 29, 2026, and it expects to submit an sNDA in Q2 2026 for ZORYVE cream 0.05% in infants ages 3 to 24 months after positive Phase 2 topline data. The company also reported it obtained a new U.S. patent extending exclusivity for its topical roflumilast foam formulation from 2041 to 2042.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602251600PRIMZONEFULLFEED9661333) on February 25, 2026, and is solely responsible for the information contained therein.
Comments